PO.PR01.05 · 预防研究
面向黑人前列腺癌幸存者的生存关怀应用程序的可行性:一项为期12周的移动健康试点研究结果
Feasibility of a survivorship app for black prostate cancer survivors: Results from a 12-week mHealth pilot study
作者与单位 Authors & Affiliations
摘要 Abstract
中文摘要
引言:与白人相比,黑人前列腺癌(CaP)幸存者在治疗后经历独特的生活质量(QoL)和康复挑战。智能手机交付的移动健康干预为症状追踪和生活方式改变提供了有前景的途径;但其在该人群中的可行性、用户参与度和可接受性仍不明确。本研究评估了面向种族多元黑人前列腺癌幸存者的生存关怀应用程序(SAFE-CaPS)的可行性、参与度和初步影响,该应用旨在改善自我监测行为和健康结局。
方法:9名黑人CaP幸存者(7名美国出生、1名非洲出生、1名加勒比出生)参加了SAFE-CaPS为期12周的试点研究。该应用提供每日症状提示(疼痛、睡眠、疲劳、性功能、焦虑、抑郁)和行为追踪(体力活动、饮食)、简要的自我管理支持,以及针对严重症状报告的医生警报。在基线和12周后评估心理健康(GAD-7和PHQ-9)和QoL(FACT-P)。可行性基于依从率(即≥70%的每日日记记录)进行评估。参与度和可接受性通过应用分析以及关于可用性和文化相关性的定性访谈进行评估。参与者通过Greenphire ClinCard获得最高125美元的补偿。调查使用SPSS v29分析,访谈使用Atlas.ti v23分析。
结果:参与者诊断时的中位年龄为56岁;6人有CaP阳性家族史,4人接受过根治性前列腺切除术。4名参与者达到了可行性阈值,8人完成了研究。大多数每日记录反映轻度疼痛、疲劳、肠道和泌尿问题以及总体良好的睡眠。若干参与者频繁报告严重的性功能障碍,且大多数日记应答显示每天体力活动<20分钟。水果/蔬菜摄入量低,约半数的每日应答显示1-2份。基线时,8名参与者焦虑极轻微,5人有中度抑郁。总体而言,从第1周到第12周,QoL在身体、情绪和功能健康方面有所改善,而社会健康随时间下降。访谈强调该应用友好的设计、易于导航和可接受性是关键优势,若干参与者突出了其简洁和易用性,并建议减少重复项目并解决轻微技术问题。
结论:SAFE-CaPS可行且被良好接受。性功能障碍、低体力活动和中度抑郁成为关键问题,凸显了在未来移动健康干预中整合心理健康、活动支持和更强参与策略的必要性。
查看英文原文 English abstract
Introduction: Black prostate cancer (CaP) survivors experience unique quality-of-life (QoL) and recovery challenges after treatment compared with their White counterparts. Smartphone-delivered mobile health interventions offer promising avenues for symptom tracking and lifestyle changes; but their feasibility, user engagement, and acceptability in this population remain unclear. This study assessed the feasibility, engagement, and preliminary impact of the Survivorship App for Ethnically Diverse Black Prostate Cancer Survivors (SAFE-CaPS), designed to improve self-monitoring behaviors and health outcomes.
Methods: Nine Black CaP survivors (seven U.S.-born, one African-born, and one Caribbean-born) participated in a 12-week pilot study of SAFE-CaPS. The app provided daily prompts for symptoms (pain, sleep, fatigue, sexual function, anxiety, depression) and behavior tracking (physical activity, diet), brief self-management support, and physician alerts for severe symptom reports. Mental health (GAD-7 and PHQ-9) and QoL (FACT-P) were assessed at baseline and after 12 weeks. Feasibility was evaluated based on adherence rates (i.e., ≥70% of daily diary entries). Engagement and acceptability were assessed via app analytics and qualitative interviews on usability and cultural relevance. Participants were compensated up to $125 via Greenphire ClinCard. Surveys were analyzed with SPSS v29, and interviews with Atlas.ti v23.
Results: Participants' median age at diagnosis was 56 years; six had a positive family history of CaP, and four had undergone radical prostatectomy. Four participants met the feasibility threshold, and eight completed the study. Most daily entries reflected mild pain, fatigue, bowel and urinary issues, and generally good sleep. Several participants frequently reported severe sexual dysfunction, and most diary responses indicated <20 minutes of physical activity per day. Fruit/vegetable intake was low, with about half of daily responses showing 1-2 servings. At baseline, eight participants had minimal anxiety, while five had moderate depression. Overall, QoL improved from week 1 to week 12 in physical, emotional, and functional well-being, while social well-being declined over time. Interviews emphasized the app's user-friendly design, ease of navigation, and acceptability as key strengths, with several participants highlighting its simplicity and ease of use, with recommendations to reduce repetitive items and address minor technical issues.
Conclusions: SAFE-CaPS was feasible and well accepted. Sexual dysfunction, low physical activity, and moderate depression emerged as key concerns, heightening the need for integrated mental health, activity support, and stronger engagement strategies in future mHealth interventions.
利益披露 Disclosure
G. Kumar, None..
P. Ghasemi, None..
Y. D. Zhao, None..
Z. Nagykaldi, None..
K. A. Dwyer, None..
A. G. McIntosh, None..
E. Kaninjing, None..
M. E. Young, None..
D. Sabrina, None..
D. Morton, None..
O. Bolajoko, None.
D. E. Kendzor,
Qnovia Other, Scientific Advisory Board of Qnovia.
M. Ogunsanya, None.